ISAL 2023 | Reprogramming leukemia cells into APCs as a novel therapeutic strategy for B-ALL
Ravi Majeti, MD, PhD, Stanford University, Stanford, CA, comments on how tumor reprogrammed-antigen presenting cells (TR-APCs) may be explored for the treatment of B-ALL. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
R.M. is on the Advisory Boards of Kodikaz Therapeutic Solutions, TenSixteen Bio, Roche, Cullgen, and 858 Therapeutics and is an inventor on a number of patents related to CD47 cancer immunotherapy licensed to Gilead Sciences. R.M. receives research support from Gilead Sciences. R.M. is a co-founder and equity holder of Pheast Therapeutics, MyeloGene, and Orbital Therapeutics.
